Debt and Lease Obligations - Additional Information (Detail) $ / shares in Units, ¥ in Millions											1 Months Ended	3 Months Ended			12 Months Ended
	Jan. 19, 2022 USD ($) Tranche $ / shares	Jan. 14, 2022 USD ($)	Oct. 01, 2021 USD ($) ft² Employee	May 28, 2021 USD ($)	Jan. 05, 2021 m² ¥ / m²	Sep. 17, 2020	Aug. 04, 2020 USD ($)	Jun. 19, 2020 USD ($)	Jun. 19, 2020 USD ($) Tranche	May 15, 2020 USD ($)	Mar. 31, 2022	Dec. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2019 CNY (¥)	Dec. 31, 2021 USD ($) qtr	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	May 28, 2021 CNY (¥)	May 15, 2020 CNY (¥)
Debt Instrument [Line Items]
Loss on extinguishment of debt																$ 10,278,000
Current portion of senior secured loan												$ 45,938,000			$ 45,938,000	70,000
Write off of deferred debt issuance costs															648,000
Revenue															$ 120,181,000	144,391,000	$ 101,229,000
Accounting Standards Update Extensible List															ASU No. 2016-02
Accounting standards adopted												true			true
Accounting standards adoption date												Jan. 01, 2019			Jan. 01, 2019
Subsequent Event | January 2022 Amendment to Credit Agreement
Debt Instrument [Line Items]
Available borrowing capacity upon approval of oral paclitaxel	$ 0
Mandatory prepayment of principal percentage	62.50%
Fee percentage	7.00%
Exit fee percentage	2.00%
Amendment fee	$ 300,000
Additional mandatory prepayment in principal		$ 12,500,000
Prepayment fee percentage	5.00%
Chinese Subsidiaries | API Facility or Sintaho API Facility | Chongqing International Biological City Development & Investment Co., Ltd
Debt Instrument [Line Items]
Area of rent free lease | m²					34,517
Lease term					10 years
Renewal lease term					10 years
Payment of monthly rent per square meter | ¥ / m²					5
Chongqing Maliu Riverside Development and Investment Co., LTD ("CQ")
Debt Instrument [Line Items]
Line of credit facility percentage of periodic payment year one														20.00%
Line of credit facility percentage of periodic payment year two														30.00%
Line of credit frequency of payments															The Company is required to repay the principal amount with accrued interest within three years after the plant receives the cGMP certification, with 20% of the total loan with accrued interest is due within the first twelve months following receiving the certification, 30% of the total loan with accrued interest due within twenty-four months, and the remaining balance with accrued interest due within thirty-six months.
Line of credit due												$ 7,849,000			$ 7,849,000	7,641,000
Chongqing MJ Medical Devices Co., Ltd
Debt Instrument [Line Items]
Controlling interest sold to non-controlling interest												100,000
China
Debt Instrument [Line Items]
Revenue															$ 2,666,000	39,796,000	$ 2,105,000
China | Chongqing Maliu Riverside Development and Investment Co., LTD ("CQ")
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity														¥ 50.0		7,700,000
Long-term line of credit, interest rate														4.75%
Senior Credit Agreements
Debt Instrument [Line Items]
Debt maturity date															Jun. 19, 2026
Loss on extinguishment of debt									$ 7,200,000
Number of tranches | Tranche									5
Debt instrument, maximum borrowing capacity								$ 225,000,000.0	$ 225,000,000.0
Available borrowing capacity upon approval of oral paclitaxel								$ 75,000,000.0	$ 75,000,000.0
Interest rate terms															The loan bears interest at a fixed annual rate of 11.0%. The Company allocated the proceeds of the drawn tranches between liability and equity components and the fair value of such equity components, along with the direct costs related to the issuance of the debt were recorded as an offset to long-term debt on the consolidated balance sheets. The debt discount and financing fees are amortized on a straight-line basis, which approximates the effective interest method, over the remaining maturity of the Senior Credit Agreement. The effective interest rate of Tranches A, B and D, including the amortization of debt discount and financing fees amounts to 13.3% annually. The Company is required to make quarterly interest-only payments until June 19, 2022, after which the Company is required to make quarterly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity.
Bearing interest at a fixed annual rate								11.00%	11.00%
Commitment fee percentage will be paid						0.60%
Exit fee liability												3,000,000.0			$ 3,000,000.0
Minimum liquidity amount in cash or permitted cash equivalent investments amount								$ 20,000,000.0	$ 20,000,000.0
Line of credit from first step up date until maturity								25,000,000.0
Line of credit facility second step up date outstanding amount								225,000,000.0
Line of credit from second step up date until maturity								$ 30,000,000.0
Minimum revenue percentage								50
Line of credit due												150,000,000.0			150,000,000.0
Senior Credit Agreements | Subsequent Event
Debt Instrument [Line Items]
Number of tranches | Tranche	2
Mandatory prepayment of principal percentage	62.50%
Fee percentage	7.00%
Exit fee percentage	2.00%
Amendment fee	$ 300,000
Additional mandatory prepayment in principal	$ 12,500,000
Prepayment fee percentage	5.00%
Purchase price | $ / shares	$ 12.63
Senior Credit Agreements | Minimum
Debt Instrument [Line Items]
Line of credit facility first step up date outstanding amount								$ 150,000,000.0
Senior Credit Agreements | Maximum
Debt Instrument [Line Items]
Covenant leverage ratio								4.50
Revenue Interest Financing Agreement | Sagard Healthcare Royalty Partners, LP
Debt Instrument [Line Items]
Licenses revenue							$ 50,000,000.0
Revenue Interest Financing Agreement | Sagard Healthcare Royalty Partners, LP | Interest Expenses
Debt Instrument [Line Items]
Write off of deferred debt issuance costs													$ 600,000
Revenue Interest Financing Agreement | Sagard Healthcare Royalty Partners, LP | Scenario Forecast
Debt Instrument [Line Items]
Agreement termination date											2022-03
Credit Agreement
Debt Instrument [Line Items]
Debt maturity date				May 28, 2022
Debt instrument, maximum borrowing capacity				$ 800,000						$ 800,000
Debt instrument, amount drawn												800,000			800,000
Credit agreement repaid date										May 14, 2021
Bearing interest at a fixed annual rate				4.35%						4.35%								4.35%	4.35%
Credit Agreement | China
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity | ¥																		¥ 5.0	¥ 5.0
Lease Agreement | New York State | GMP Pharmaceutical Manufacturing Plant
Debt Instrument [Line Items]
Lease term			10 years
Renewal lease term			10 years
Area of building space built under agreement | ft²			409,000
Payment of annual rent			$ 2
Lease Agreement | Maximum | New York State | GMP Pharmaceutical Manufacturing Plant
Debt Instrument [Line Items]
Fund for construction costs			$ 208,000,000.0
Lease Agreement and 2015 Agreement
Debt Instrument [Line Items]
Number of employee committed to hire within 5 years | Employee			450
Term of committed to hire employee first period			5 years
Number of employee committed to hire within 2.5 years | Employee			300
Term of committed to hire minimum employee			2 years 6 months
Lease Agreement and 2015 Agreement | New York State | GMP Pharmaceutical Manufacturing Plant
Debt Instrument [Line Items]
Operating expenses committed to spent in first 10 year term			$ 1,520,000,000
Operating expenses committed to spent in second 10 year term			$ 1,500,000,000
Dunkirk Transaction
Debt Instrument [Line Items]
Current portion of senior secured loan												45,900,000			$ 45,900,000
Number Of quarterly payments | qtr															3
Senior secured loan as long-term debt												95,400,000			$ 95,400,000
Debt discount and financing fees												8,700,000			8,700,000
Dunkirk Transaction | Quarterly Payment One
Debt Instrument [Line Items]
Current portion of senior secured loan												2,800,000			2,800,000
Dunkirk Transaction | Quarterly Payment Two
Debt Instrument [Line Items]
Current portion of senior secured loan												25,000,000.0			25,000,000.0
Dunkirk Transaction | Quarterly Payment Three
Debt Instrument [Line Items]
Current portion of senior secured loan												12,500,000			12,500,000
Tranche A,B and D | Senior Credit Agreements
Debt Instrument [Line Items]
Amortization of debt discount financing fees percentage								13.30%	13.30%
Debt instrument, amount drawn												150,000,000.0			150,000,000.0
Tranche C and E | Senior Credit Agreements
Debt Instrument [Line Items]
Debt instrument, amount drawn												75,000,000.0			75,000,000.0
Senior Secured Loan
Debt Instrument [Line Items]
Principal value of loan												50,000,000.0			$ 50,000,000.0
Debt maturity date															Jun. 30, 2023
Prepayment fee								$ 3,800,000
Unamortized debt discount								3,100,000	$ 3,100,000
Other charges								300,000
Loss on extinguishment of debt								$ 7,200,000
Senior secured loan as long-term debt												$ 95,400,000			$ 95,400,000	$ 138,399,000
Senior Secured Loan | LIBOR
Debt Instrument [Line Items]
Debt variable rate basis floor															2.00%
Basis spread on variable rate															9.00%